Emerging HIFU technology shows promise in men with prostate cancer

Patients who underwent treatment with SBRT demonstrated a 5-year disease control rate of 96%, compared with 95% among patients who underwent conventionally fractionated radiation therapy.

In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.

"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.

The PSE test was shown to improve the predictive accuracy of a standard PSA test from 55% to 94%.

In the first article of this series, Naveen Kella, MD, discusses the transformative impact of PSMA PET-CT imaging on prostate cancer diagnosis, highlighting its advantages and addressing clinical challenges and guidelines in this evolving field.